Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. filed this Form 8-K on November 7, 2016, to disclose an inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2016. The delay is due to a required restatement of financial statements for the "Non-Reliance Periods" (Q3 2014 through Q2 2016) following a review by the SEC's Office of the Chief Accountant (OCA).
Key Financial Metrics and Liquidity
- Cash Position: As of September 30, 2016, the Company held $147.4 million in cash, cash equivalents, and marketable securities, compared to $117.2 million at December 31, 2015. The restatement has no impact on the cash position.
- Net Product Sales:
- FY 2014: $89.6 million (unchanged by restatement).
- FY 2015: $143.5 million (unchanged by restatement).
- Three months ended Sept 30, 2016: $55.6 million.
- Nine months ended Sept 30, 2016: $149.0 million.
- Operating Income (Three and Nine Months Ended Sept 30, 2016):
- With anticipated restatement effects: Approximately $20.0 million (3 months) and $38.9 million (9 months).
- Excluding restatement effects: $19.0 million (3 months) and $34.9 million (9 months).
- Debt: The $30 million royalty monetization transaction, previously recorded as revenue, is being reclassified as non-recourse debt. The Company has no obligation to repay this debt in cash; it will be amortized as royalty payments are received by the counterparty.
Material Changes and Restatement Details
The primary material change involves the reclassification of a $30 million royalty monetization transaction entered into in July 2014.
- Accounting Change: The transaction will be recorded as non-recourse debt rather than revenue. Consequently, revenue and operating income for Q3 2014 will be reduced by approximately $30 million.
- Future Recognition: Royalties received by the counterparty will now be recognized by the Company as non-cash royalty revenue, reducing the debt balance by the same amount less non-cash implied interest expense.
- Impact on Expenses: The restatement is not expected to impact net product sales or operating expenses for the periods ended December 31, 2014, and 2015.
Guidance, Outlook, and Risks
The Company has adjusted its full-year 2016 guidance to reflect the anticipated effects of the restatement:
- Net Product Sales: Adjusted to a range of $205 million to $210 million (previously $200 million to $210 million).
- R&D Expenses: Adjusted to a range of $40 million to $44 million (previously $50 million to $55 million).
- Operating Income:
- With restatement effects: $46 million to $51 million.
- Excluding restatement effects: $42 million to $47 million (previously $32 million to $37 million).
Risks and Contingencies: The Company identified a material weakness in internal control over financial reporting. It intends to file the restated reports by the end of 2016 but noted there can be no assurance of this timeline. Forward-looking statements are subject to risks regarding the final conclusion of the audit committee's review and potential additional adjustments.
Investor Verification Checklist
- Verify the final restated financial statements for the Non-Reliance Periods (Q3 2014 through Q2 2016) once filed.
- Confirm the specific details of the material weakness in internal controls and the remediation plan.
- Monitor the timing of the delayed Form 10-Q filing for the quarter ended September 30, 2016.
- Review the updated full-year 2016 guidance against actual results upon year-end close.